• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加泰罗尼亚常染色体显性高胆固醇血症患者中的多基因标记:加权低密度脂蛋白胆固醇升高单核苷酸多态性评分的分布及变异选择的优化

Polygenic Markers in Patients Diagnosed of Autosomal Dominant Hypercholesterolemia in Catalonia: Distribution of Weighted LDL-c-Raising SNP Scores and Refinement of Variant Selection.

作者信息

Martín-Campos Jesús M, Ruiz-Nogales Sheila, Ibarretxe Daiana, Ortega Emilio, Sánchez-Pujol Elisabet, Royuela-Juncadella Meritxell, Vila Àlex, Guerrero Carolina, Zamora Alberto, Soler I Ferrer Cristina, Arroyo Juan Antonio, Carreras Gemma, Martínez-Figueroa Susana, Roig Rosa, Plana Núria, Blanco-Vaca Francisco

机构信息

Metabolic Bases of Cardiovascular Risk Group, Santa Creu i Sant Pau Hospital Research Institute (IR-HSCSP)-Sant Pau Biomedical Research Institute (IIB-Sant Pau), 08041 Barcelona, Spain.

Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM), 28029 Madrid, Spain.

出版信息

Biomedicines. 2020 Sep 15;8(9):353. doi: 10.3390/biomedicines8090353.

DOI:
10.3390/biomedicines8090353
PMID:32942679
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7554998/
Abstract

Familial hypercholesterolemia (FH) is associated with mutations in the low-density lipoprotein (LDL) receptor (), apolipoprotein B (), and proprotein convertase subtilisin/kexin 9 () genes. A pathological variant has not been identified in 30-70% of clinically diagnosed FH patients, and a burden of LDL cholesterol (LDL-c)-raising alleles has been hypothesized as a potential cause of hypercholesterolemia in these patients. Our aim was to study the distribution of weighted LDL-c-raising single-nucleotide polymorphism (SNP) scores (weighted gene scores or wGS) in a population recruited in a clinical setting in Catalonia. The study included 670 consecutive patients with a clinical diagnosis of FH and a prior genetic study involving 250 mutation-positive (FH/M+) and 420 mutation-negative (FH/M-) patients. Three wGSs based on LDL-c-raising variants were calculated to evaluate their distribution among FH patients and compared with 503 European samples from the 1000 Genomes Project. The FH/M- patients had significantly higher wGSs than the FH/M+ and control populations, with sensitivities ranging from 42% to 47%. A wGS based only on the SNPs significantly associated with FH (wGS8) showed a higher area under the receiver operating characteristic curve, and higher diagnostic specificity and sensitivity, with 46.4% of the subjects in the top quartile. wGS8 would allow for the assignment of a genetic cause to 66.4% of the patients if those with polygenic FH are added to the 37.3% of patients with monogenic FH. Our data indicate that a score based on 8 SNPs and the75th percentile cutoff point may identify patients with polygenic FH in Catalonia, although with limited diagnostic sensitivity and specificity.

摘要

家族性高胆固醇血症(FH)与低密度脂蛋白(LDL)受体、载脂蛋白B和前蛋白转化酶枯草杆菌蛋白酶/kexin 9基因的突变有关。在30%至70%临床诊断为FH的患者中未发现病理性变异,并且有人推测升高低密度脂蛋白胆固醇(LDL-c)的等位基因负荷是这些患者高胆固醇血症的一个潜在原因。我们的目的是研究在加泰罗尼亚临床环境中招募的人群中加权LDL-c升高单核苷酸多态性(SNP)评分(加权基因评分或wGS)的分布情况。该研究纳入了670例临床诊断为FH的连续患者,以及一项先前的基因研究,其中包括250例突变阳性(FH/M+)和420例突变阴性(FH/M-)患者。计算了基于升高LDL-c变异的三种wGS,以评估它们在FH患者中的分布,并与来自千人基因组计划的503个欧洲样本进行比较。FH/M-患者的wGS显著高于FH/M+患者和对照人群,敏感性范围为42%至47%。仅基于与FH显著相关的SNP的wGS(wGS8)在受试者工作特征曲线下面积更大,诊断特异性和敏感性更高,处于最高四分位数的受试者占46.4%。如果将多基因FH患者添加到单基因FH患者的37.3%中,wGS8将能够为66.4%的患者确定遗传原因。我们的数据表明,基于8个SNP和第75百分位数截止点的评分可能识别出加泰罗尼亚的多基因FH患者,尽管诊断敏感性和特异性有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b7/7554998/d20d2afaf3e0/biomedicines-08-00353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b7/7554998/81d078107180/biomedicines-08-00353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b7/7554998/d20d2afaf3e0/biomedicines-08-00353-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b7/7554998/81d078107180/biomedicines-08-00353-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d9b7/7554998/d20d2afaf3e0/biomedicines-08-00353-g002.jpg

相似文献

1
Polygenic Markers in Patients Diagnosed of Autosomal Dominant Hypercholesterolemia in Catalonia: Distribution of Weighted LDL-c-Raising SNP Scores and Refinement of Variant Selection.加泰罗尼亚常染色体显性高胆固醇血症患者中的多基因标记:加权低密度脂蛋白胆固醇升高单核苷酸多态性评分的分布及变异选择的优化
Biomedicines. 2020 Sep 15;8(9):353. doi: 10.3390/biomedicines8090353.
2
Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries.用于临床家族性高胆固醇血症多基因形式诊断的低密度脂蛋白胆固醇遗传风险评分的变异选择优化及在6个国家样本中的验证
Clin Chem. 2015 Jan;61(1):231-8. doi: 10.1373/clinchem.2014.231365. Epub 2014 Nov 20.
3
Children with hypercholesterolemia of unknown cause: Value of genetic risk scores.病因不明的高胆固醇血症患儿:遗传风险评分的价值。
J Clin Lipidol. 2016 Jul-Aug;10(4):851-859. doi: 10.1016/j.jacl.2016.02.017. Epub 2016 Mar 21.
4
Polygenic contribution for familial hypercholesterolemia (FH).家族性高胆固醇血症(FH)的多基因贡献。
Curr Opin Lipidol. 2021 Dec 1;32(6):392-395. doi: 10.1097/MOL.0000000000000787.
5
Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.德国家族性高胆固醇血症患者的临床特征及突变谱。
Atherosclerosis. 2016 Oct;253:88-93. doi: 10.1016/j.atherosclerosis.2016.08.037. Epub 2016 Aug 26.
6
Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations.在一个有或没有致病突变的临床诊断家族性高胆固醇血症的大队列患者中,十二种变体低密度脂蛋白胆固醇分布多基因评分。
J Am Heart Assoc. 2022 Apr 5;11(7):e023668. doi: 10.1161/JAHA.121.023668. Epub 2022 Mar 24.
7
A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia.基于新一代测序的新的 165-SNP 低密度脂蛋白胆固醇多基因风险评分在家族性高胆固醇血症的常规诊断中优于先前发表的评分。
Transl Res. 2023 May;255:119-127. doi: 10.1016/j.trsl.2022.12.002. Epub 2022 Dec 15.
8
Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease.单基因与多基因高胆固醇血症与动脉粥样硬化性心血管疾病风险的关联。
JAMA Cardiol. 2020 Apr 1;5(4):390-399. doi: 10.1001/jamacardio.2019.5954.
9
Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?遗传性高胆固醇血症家系中基因风险评分对表型模拟的识别作用?
Eur J Hum Genet. 2018 Apr;26(4):570-578. doi: 10.1038/s41431-017-0078-y. Epub 2018 Jan 26.
10
Clinical utility of the polygenic LDL-C SNP score in familial hypercholesterolemia.载脂蛋白 LDL-C 多基因 SNP 评分在家族性高胆固醇血症中的临床应用。
Atherosclerosis. 2018 Oct;277:457-463. doi: 10.1016/j.atherosclerosis.2018.06.006.

引用本文的文献

1
An 8-SNP LDL Cholesterol Polygenic Score: Associations with Cardiovascular Risk Traits, Familial Hypercholesterolemia Phenotype, and Premature Coronary Heart Disease in Central Romania.一个包含 8 个单核苷酸多态性的 LDL 胆固醇多基因评分:与心血管风险特征、家族性高胆固醇血症表型和罗马尼亚中部的早发性冠心病的相关性。
Int J Mol Sci. 2024 Sep 18;25(18):10038. doi: 10.3390/ijms251810038.
2
The association between polymorphism of LDL-R gene and ischemic stroke risk in Chinese population: A meta-analysis.中国人群低密度脂蛋白受体(LDL-R)基因多态性与缺血性卒中风险的关联:一项荟萃分析。
Heliyon. 2024 Feb 12;10(4):e26314. doi: 10.1016/j.heliyon.2024.e26314. eCollection 2024 Feb 29.
3

本文引用的文献

1
Repositioning of the global epicentre of non-optimal cholesterol.非最佳胆固醇的全球中心位置的重新定位。
Nature. 2020 Jun;582(7810):73-77. doi: 10.1038/s41586-020-2338-1. Epub 2020 Jun 3.
2
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis.家族性高胆固醇血症在普通人群和动脉粥样硬化性心血管疾病患者中的患病率:系统评价和荟萃分析。
Circulation. 2020 Jun 2;141(22):1742-1759. doi: 10.1161/CIRCULATIONAHA.119.044795. Epub 2020 May 29.
3
Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.
Polygenic Risk of Hypertriglyceridemia Is Modified by BMI.
BMI 可修饰致高甘油三酯血症的多基因风险。
Int J Mol Sci. 2022 Aug 30;23(17):9837. doi: 10.3390/ijms23179837.
4
Genetic Determinants of Plasma Low-Density Lipoprotein Cholesterol Levels: Monogenicity, Polygenicity, and "Missing" Heritability.血浆低密度脂蛋白胆固醇水平的遗传决定因素:单基因性、多基因性及“缺失”的遗传力
Biomedicines. 2021 Nov 19;9(11):1728. doi: 10.3390/biomedicines9111728.
全球家族性高胆固醇血症患病率的Meta 分析:1100 万例患者研究
J Am Coll Cardiol. 2020 May 26;75(20):2553-2566. doi: 10.1016/j.jacc.2020.03.057.
4
A polygenic biomarker to identify patients with severe hypercholesterolemia of polygenic origin.一种多基因生物标志物,用于识别多基因起源的严重高胆固醇血症患者。
Mol Genet Genomic Med. 2020 Jun;8(6):e1248. doi: 10.1002/mgg3.1248. Epub 2020 Apr 19.
5
The effect of apolipoprotein E polymorphism on serum metabolome - a population-based 10-year follow-up study.载脂蛋白 E 多态性对血清代谢组的影响 - 一项基于人群的 10 年随访研究。
Sci Rep. 2019 Jan 24;9(1):458. doi: 10.1038/s41598-018-36450-9.
6
The evolution of genetic-based risk scores for lipids and cardiovascular disease.基于遗传的血脂和心血管疾病风险评分的演变。
Curr Opin Lipidol. 2019 Apr;30(2):71-81. doi: 10.1097/MOL.0000000000000576.
7
Autosomal dominant hypercholesterolemia in Catalonia: Correspondence between clinical-biochemical and genetic diagnostics in 967 patients studied in a multicenter clinical setting.加泰罗尼亚常染色体显性高胆固醇血症:多中心临床环境中研究的 967 例患者的临床生物化学与基因诊断的相关性。
J Clin Lipidol. 2018 Nov-Dec;12(6):1452-1462. doi: 10.1016/j.jacl.2018.09.002. Epub 2018 Sep 7.
8
Unusual genetic variants associated with hypercholesterolemia in Argentina.阿根廷高胆固醇血症相关的罕见遗传变异。
Atherosclerosis. 2018 Oct;277:256-261. doi: 10.1016/j.atherosclerosis.2018.06.009.
9
Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).超过 60 个国家家族性高胆固醇血症治疗现状概述 - EAS 家族性高胆固醇血症研究协作组(FHSC)。
Atherosclerosis. 2018 Oct;277:234-255. doi: 10.1016/j.atherosclerosis.2018.08.051.
10
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals.在 16324 个人中进行深度覆盖全基因组序列和血脂检测。
Nat Commun. 2018 Aug 23;9(1):3391. doi: 10.1038/s41467-018-05747-8.